Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia 2Plasmacytoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematologic Neoplasms 1Esophageal Squamous Cell Carcinoma 1

Interventions

Rituximab 130Cyclophosphamide 41Bendamustine Hydrochloride 39venetoclax 25fludarabine 25obinutuzumab 24Lenalidomide 23ibrutinib 22Gemcitabine 22Vincristine 20Prednisone 20tositumomab I-131 19Doxorubicin 19plerixafor 14Dexamethasone 14Granulocyte Colony-Stimulating Factor 12pirtobrutinib 11Brentuximab Vedotin 11glofitamab 10tocilizumab 9pembrolizumab 9ibritumomab tiuxetan 9Etoposide 9Azacitidine 9polatuzumab vedotin 8parsaclisib 8copanlisib 8acalabrutinib 8Drug Therapy 8ublituximab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Non-Hodgkin × CF regimen × Clear all
NCT04666168 2020-12-14

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
200 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡